Procurement Summary
Country: USA
Summary: Cryopreserved Platelets Cpp for Us Fda Licensure
Deadline: 04 May 2026
Posting Date: 24 Apr 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 140049178
Document Ref. No.: HT9427-26-RFI-705
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Defense Health Agency seeks to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation. We develop, directly through collaboration with commercial partners, medical products that enhance readiness and improve the quality of life of active-duty personnel in the operational environment. OPMED-s WPAC PMO has been developing a biologic product: Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen, biologic-platelet product. DMSO CPP are formulated to provide a platelet-derived product with a longer shelf life (2 years and potentially longer) than liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20ºC to 24ºC) under gentle agitation.
Notice ID: ht9427-26-rfi-705
Department/Ind. Agency: dept of defense
Sub-tier: defense health agency (dha)
Office: army med res acq activity
NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Inactive Dates: may 19, 2026
Inactive Policy: 15 days after response date
Documents
Tender Notice
Documents.zip